Solara Active Pharma Sciences Limited

NSEI:SOLARA Stok Raporu

Piyasa değeri: ₹36.6b

Solara Active Pharma Sciences Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

Solara Active Pharma Sciences şirketinin toplam hissedar öz sermayesi ₹10.9B ve toplam borcu ₹8.2B olup, bu da borç-öz sermaye oranını 75.3% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla ₹22.9B ve ₹12.0B dir.

Anahtar bilgiler

75.3%

Borç/özkaynak oranı

₹8.20b

Borç

Faiz karşılama oranın/a
Nakit₹60.70m
Eşitlik₹10.89b
Toplam yükümlülükler₹12.01b
Toplam varlıklar₹22.90b

Son finansal sağlık güncellemeleri

Recent updates

The Market Lifts Solara Active Pharma Sciences Limited (NSE:SOLARA) Shares 26% But It Can Do More

Sep 13
The Market Lifts Solara Active Pharma Sciences Limited (NSE:SOLARA) Shares 26% But It Can Do More

Further Upside For Solara Active Pharma Sciences Limited (NSE:SOLARA) Shares Could Introduce Price Risks After 30% Bounce

Jul 20
Further Upside For Solara Active Pharma Sciences Limited (NSE:SOLARA) Shares Could Introduce Price Risks After 30% Bounce

Slammed 32% Solara Active Pharma Sciences Limited (NSE:SOLARA) Screens Well Here But There Might Be A Catch

Jun 05
Slammed 32% Solara Active Pharma Sciences Limited (NSE:SOLARA) Screens Well Here But There Might Be A Catch

A Look At The Fair Value Of Solara Active Pharma Sciences Limited (NSE:SOLARA)

May 11
A Look At The Fair Value Of Solara Active Pharma Sciences Limited (NSE:SOLARA)

Investors Still Aren't Entirely Convinced By Solara Active Pharma Sciences Limited's (NSE:SOLARA) Revenues Despite 28% Price Jump

Apr 19
Investors Still Aren't Entirely Convinced By Solara Active Pharma Sciences Limited's (NSE:SOLARA) Revenues Despite 28% Price Jump

Is Solara Active Pharma Sciences (NSE:SOLARA) A Risky Investment?

Mar 13
Is Solara Active Pharma Sciences (NSE:SOLARA) A Risky Investment?

Even With A 26% Surge, Cautious Investors Are Not Rewarding Solara Active Pharma Sciences Limited's (NSE:SOLARA) Performance Completely

Feb 23
Even With A 26% Surge, Cautious Investors Are Not Rewarding Solara Active Pharma Sciences Limited's (NSE:SOLARA) Performance Completely

Further Upside For Solara Active Pharma Sciences Limited (NSE:SOLARA) Shares Could Introduce Price Risks After 25% Bounce

Jan 04
Further Upside For Solara Active Pharma Sciences Limited (NSE:SOLARA) Shares Could Introduce Price Risks After 25% Bounce

Solara Active Pharma Sciences Limited's (NSE:SOLARA) Intrinsic Value Is Potentially 81% Above Its Share Price

May 12
Solara Active Pharma Sciences Limited's (NSE:SOLARA) Intrinsic Value Is Potentially 81% Above Its Share Price

Estimating The Intrinsic Value Of Solara Active Pharma Sciences Limited (NSE:SOLARA)

Nov 08
Estimating The Intrinsic Value Of Solara Active Pharma Sciences Limited (NSE:SOLARA)

Is Solara Active Pharma Sciences (NSE:SOLARA) A Risky Investment?

Sep 30
Is Solara Active Pharma Sciences (NSE:SOLARA) A Risky Investment?

Are Investors Undervaluing Solara Active Pharma Sciences Limited (NSE:SOLARA) By 22%?

Aug 03
Are Investors Undervaluing Solara Active Pharma Sciences Limited (NSE:SOLARA) By 22%?

Solara Active Pharma Sciences (NSE:SOLARA) Is Making Moderate Use Of Debt

Jun 19
Solara Active Pharma Sciences (NSE:SOLARA) Is Making Moderate Use Of Debt

Newsflash: Solara Active Pharma Sciences Limited (NSE:SOLARA) Analysts Have Been Trimming Their Revenue Forecasts

Feb 17
Newsflash: Solara Active Pharma Sciences Limited (NSE:SOLARA) Analysts Have Been Trimming Their Revenue Forecasts

A Look At The Fair Value Of Solara Active Pharma Sciences Limited (NSE:SOLARA)

Dec 21
A Look At The Fair Value Of Solara Active Pharma Sciences Limited (NSE:SOLARA)

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: SOLARA 'nin kısa vadeli varlıkları ( ₹7.6B ) kısa vadeli yükümlülüklerini ( ₹10.5B ) kapsamıyor.

Uzun Vadeli Yükümlülükler: SOLARA şirketinin kısa vadeli varlıkları ( ₹7.6B ) uzun vadeli yükümlülüklerini ( ₹1.5B ) aşmaktadır.


Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: SOLARA 'nin net borç/öz sermaye oranı ( 74.7% ) yüksek olarak değerlendiriliyor.

Borcun Azaltılması: SOLARA şirketinin borç/öz sermaye oranı son 5 yılda 58.2% seviyesinden 75.3% seviyesine yükseldi.


Bilanço


Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: Kârsız olan SOLARA mevcut pozitif serbest nakit akışı seviyesini koruduğu takdirde 3 yıldan fazla yetecek nakit pistine sahip olacaktır.

Tahmini Nakit Akışı: SOLARA kârlı değildir ancak serbest nakit akışı pozitif olsa ve yılda 4.7 % oranında azalsa bile 3 yıldan fazla bir süre yetecek nakit akışına sahiptir.


Sağlıklı şirketleri keşfedin